StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie kaletra (lopinavir/ritonavir) [legacy through FY20Q1] — International net revenues ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues

Latest, Q1 2020
72
Period ended Mar 31, 2020
Change on a year earlier
+10.8%
65 in Q1 2019
History
13 quarters
Since Q1 2017
Sources
8
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKaletra (lopinavir/ritonavir) [legacy through FY20Q1] — International net revenues ($M) ($M)Year on yearSource
Q1 2020Mar 31, 202072+10.8%Form 10-Q (filed 2020-05-08) ↗
Q4 2019Dec 31, 201946-35.2%Form 10-K (filed 2020-02-21) ↗
Q3 2019Sep 30, 201967-6.9%Form 10-Q (filed 2019-11-06) ↗
Q2 2019Jun 30, 201967-14.1%Form 10-Q (filed 2019-08-05) ↗
Q1 2019Mar 31, 201965+8.3%Form 10-Q (filed 2020-05-08) ↗
Q4 2018Dec 31, 201871-26.0%Form 10-K (filed 2020-02-21) ↗
Q3 2018Sep 30, 201872+4.3%Form 10-Q (filed 2019-11-06) ↗
Q2 2018Jun 30, 201878-14.3%Form 10-Q (filed 2019-08-05) ↗
Q1 2018Mar 31, 201860-37.5%Form 10-Q (filed 2019-05-03) ↗
Q4 2017Dec 31, 201796–Form 10-K (filed 2020-02-21) ↗
Q3 2017Sep 30, 201769–Form 10-Q (filed 2018-11-07) ↗
Q2 2017Jun 30, 201791–Form 10-Q (filed 2018-08-07) ↗
Q1 2017Mar 31, 201796–Form 10-Q (filed 2018-05-04) ↗

Cite this data

StockData. (2026). AbbVie Kaletra (lopinavir/ritonavir) [legacy through FY20Q1] — International net revenues ($M) ($M), quarterly Q1 2017–Q1 2020 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/kaletra_intl

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.